Talk:Puberty blocker

Sources

The 2020 review by Rew and the 2024 review by Baxendale are available at no charge to editors through Wikipedia:The Wikipedia Library.

There is also free access to these papers:

• Wenner, Danielle M.; George, B. R. (November 2021). "Not just a tragic compromise: The positive case for adolescent access to puberty‐blocking treatment". Bioethics. 35 (9): 925–931. doi:10.1111/bioe.12929. ISSN 0269-9702.
• Boskey, Elizabeth R. (2019-12-20). "Transgender Youth: Development of the Self in Adolescence Gender". In Hupp, Stephen; Jewell, Jeremy (eds.). The Encyclopedia of Child and Adolescent Development (1 ed.). Wiley. doi:10.1002/9781119171492.wecad481. ISBN 978-1-119-16189-9.
• Ludvigsson, Jonas F.; Adolfsson, Jan; Höistad, Malin; Rydelius, Per‐Anders; Kriström, Berit; Landén, Mikael (November 2023). "A systematic review of hormone treatment for children with gender dysphoria and recommendations for research". Acta Paediatrica. 112 (11): 2279–2292. doi:10.1111/apa.16791. ISSN 0803-5253. (open access)

which might interest some of the regular editors. These are all on the Wiley site. Try these steps:

1. Go to https://wikipedialibrary.wmflabs.org/ and login with your regular Wikipedia account.
2. Under "My Collections", almost at the end of the page, find the box for Wiley. Click on the blue "Access collection" button.
3. That will take you to the Wiley search page. Put the title of the article/chapter/book into the main search box.
4. Click on the matching result. Some of them display on the page, and some require you to download the PDF. (Downloading a whole textbook takes a long time. I've had better results with picking and choosing chapters.)

Please let me know if you found this helpful. WhatamIdoing (talk) 21:42, 1 June 2024 (UTC)

Change to lede

This is going to be a contentious topic and probably has been discussed on this page before, but I propose mentioning the fact that several systematic reviews have failed to find conclusive evidence about the potential psychosocial impact of puberty blockers. Mentioning that rising scepticism in the field of medicine has made puberty suppression the subject of public controversy is vague and doesn't do justice to the reasons why this is the case. Therefore, I propose adding at least a sentence along the following lines: Several systematic reviews failed to find conclusive evidence that puberty suppression improves psychosocial health in transgender adolescents. We may like to add reasons why this is the case (e.g., due to small sample sizes, heterogeneity of results, unreported data etc.), but at least some mention of the current research status in the lede is necessary for the balance of this article.

PS: I'll leave discussing whether or not we should make a distiniction on the basis of consensus-based and evidence-based support for puberty blockers up to others. Cixous (talk) 15:00, 12 July 2024 (UTC)

Yes it has been discussed a lot - see eg. https://en.wikipedia.org/wiki/Talk:Puberty_blocker/Archive_4#Cass_Review

I agree that this needs mentioning in the lede. Void if removed (talk) 15:23, 12 July 2024 (UTC)

Thanks for linking the previous discussion! I think there is enough of a case to mention it in the lede. We have Taylor et al. (2024) and Ludvigsson et al. (2023) who, broadly speaking, come to the same conclusion. Their findings aren't great news either - the Endocrine Society guideline from 2017 stated that there was low quality evidence for puberty suppression (p. 3 for those interested).

I'll give others some time to react as well, but if there's no major objection, I'll add it to the lede. Cixous (talk) 17:35, 12 July 2024 (UTC)

Yes, this is due - and overdue. The consensus-based vs evidence-based distinction seems close to the truth of the matter, but I’m not sure if RSes frame it that way Barnards.tar.gz (talk) 18:12, 12 July 2024 (UTC)

On the consensus-based vs evidence-based distinction: the best explanation thus far I've found is in the BMJ podcast episode with Hillary Cass, though I don't think this is the best source out there. It's a less than ideal situation, not in the least because being consensus-based is a tendentious claim that the medical organisations in question deny. Cixous (talk) 18:34, 12 July 2024 (UTC)

I would support a change to the lead that gives us a weightier summary of §Research status. I'd prefer to more closely match the section's language with something like "Several systematic reviews found that evidence of the effectiveness of puberty suppression in transgender adolescents is low in quality. As for the rest of the section, maybe something like "Critics of the reviews' methodology have said that high-quality evidence like randomized controlled trials would be unethical to obtain."? Firefangledfeathers (talk / contribs) 18:32, 12 July 2024 (UTC)

I wouldn't go for 'effectiveness', but stick closer to what the actual research articles are saying, i.e. 'psychosocial outcome' and/or 'cognitive effects'. After all, puberty suppression is effective when it comes to just that - puberty suppression. Phrasing it as a matter of effectiveness hopelessly obfuscates the matter. Lastly, I support adding a few sentences on critics, though I'm skeptical of 'randomised controlled trials' as proper criticism. No one is actually proposing giving one cohort of trans kids puberty blockers and others a placebo to see if mental health improves for the simple reason that this would never get past an ethics committee. Cixous (talk) 18:41, 12 July 2024 (UTC)

I prefer to go WP:LEADFOLLOWSBODY. Do you think the body needs to be adjusted, since it also mentions RCTs? You've sort of landed on the main point of the criticism there, since the upper tier is (at least according to the cited sources) reserved for RCTs. If I grade you on a 6 point scale but we all agree it would be unethical for you to get a 6, we probably haven't selected the best scale. Good point on effectiveness. How about "Several systematic reviews found that evidence supporting the use of puberty suppression in transgender adolescents is low in quality."? Firefangledfeathers (talk / contribs) 18:45, 12 July 2024 (UTC)

I understand where you're coming from, but I'd like to be as specific as possible here. A proper systematic review only synthesises high- or moderate-quality evidence, so stating that they found the evidence was 'low' is not what they did. If anything, it'd be appropriate to state the evidence was weak. As the most recent (and AFAIK only; could have gone into sexual development as well, but I forgot about that) specifically mention psychosocial outcomes and cognitive effects, I'd stick to being precise about that. That being said, I'm okay with writing things differently if that's what the majority of editors want.

On the adjusting of the body: I think the entire article could benefit from some rewriting (I'd even go as far as removing the entire 'political challenges' section, as it's practically geared to a US context). Discussions about RCTs have their place, but I think this criticism is missing the point. As Ludvigsson et al. (2023, p. 2288) points out: However, controlled trials do not necessarily require placebo treatment, but could for example build on the date or time of starting hormonal therapy to generate comparison group (i.e., controlled trials do not mean you have to deny participants endocrinological interventions). Cixous (talk) 19:02, 12 July 2024 (UTC)

Didn't the reviews synthesize high- or moderate-quality studies, but still find the evidence to be of low quality? Firefangledfeathers (talk / contribs) 19:14, 12 July 2024 (UTC)

You could phrase it that way, though I usually stick to high/low-quality studies and weak/strong evidence. That being said, I don't believe there's a right or wrong here. Cixous (talk) 20:12, 12 July 2024 (UTC)

Re choosing the right scale - we value RCTs because of their ability to distinguish the treatment effects from the placebo effect. If a treatment cannot be subjected to a RCT, that doesn’t mean the treatment gets an automatic pass - it means there is an upper bound to the certainty we can obtain. It’s possible that someone will figure out a way to do an ethical RCT for this treatment, and it’s possible that someone will find some other way to reject the null hypothesis. It’s also possible that we can’t find such alternatives, and only weaker evidence is attainable, in which case that upper bound on certainty would remain.

I am reminded of string theory - an attractive idea that has proven resistant to empirical testing. We might believe it to be impossible to test. If that were the case, the right stance would be to treat it as a provisional or tentative or hypothetical theory - with low certainty. The wrong stance would be to use a weaker form of empiricism (e.g. simulation), and treat the claim as true because it passed the weaker test. Barnards.tar.gz (talk) 19:22, 12 July 2024 (UTC)

That makes sense, though I wouldn't have said anyone's asking for a free pass, just a better measurement tool. To be clear, I don't think we need to hash it out. If we want to summarize the criticism present in the body, this seems like one chunk that gets enough weight for a lead mention. Firefangledfeathers (talk / contribs) 19:33, 12 July 2024 (UTC)

I'm fine with mentioning it in the lede, but we should make sure that it isn't presented as an argument against the systematic reviews. After all, the systematic reviews (especially Taylor et al.) do no object to the absence of RTCs, but to the absence of high-quality evidence with homogenous results. Cixous (talk) 20:15, 12 July 2024 (UTC)

Aren't the sources we're citing presenting this as an argument against the systematic reviews? Firefangledfeathers (talk / contribs) 20:49, 12 July 2024 (UTC)

I believe the current article represents it's sources somewhat ambiguously. The statement The use of puberty blockers for gender-affirming care has attracted some criticism, due primarily to the lack of randomized controlled trials within the research base doesn't reference any sources that criticise the lack of RTCs, but sources that state the use of RTCs is unethical. It would be more logical to phrase that as Scientists regard randomized controlled trials as unethical for testing the efficacy of puberty blockers. Again, I'd like to point out that this is a completely normal, even redundant thing to say, because an ethics committee would never approve of an RCT in this case. That doesn't automatically mean that you can't do controlled studies (i.e., including an untreated comparator group, such as adolescents on a waiting list/pre-post studies where you compare a treated group with patients who got to a clinic for their first meeting/non-gender dysphoric adolescents of the same age and/or social background). The NICE review (p. 45-46) actually criticised earlier studies for their lack of comparators while stating that RTCs may well be unfeasible.

The other major source for the Research status section is Cal Horton's analysis. Without going into major detail about their stance against the GRADE approach used by NICE, it is important to note that they criticise the NICE Review and the Interim report of the Cass Review, and not the commissioned systematic reviews. While the NICE reviews evidence for the purpose of healthcare recommendations, it is not a systematic review (as in, a meta-analysis).

So, to finally answer your question, the sources do not present it as an argument against the systematic reviews, but (a) they're somewhat unfortunately represented in the body, and (b) most of what they're saying isn't actually super revolutionary or even necessary. No one is actually saying (barring the nitwits at SEGM, obviously) that we should use RTCs, not even the systematic reviews. As a result, I don't feel mentioning criticism of emphasis on RTCs is a right move at all, because the systematic reviews aren't doing that and the sources critising RTCs do not pertain to these. Cixous (talk) 14:29, 13 July 2024 (UTC)

I would support mentioning this if contextualized properly, something like Systemic reviews have found puberty suppression improves psychosocial functioning with a low certainty but noted that could be evidence it is effective in preventing dysphoria and associated mental health conditions from worsening due to incongruent puberty.

The research status section says the NICE review says it is plausible, however, that a lack of difference in scores from baseline to follow-up is the effect of GnRH analogues in children and adolescents with gender dysphoria, in whom the development of secondary sexual characteristics might be expected to be associated with an increased impact on gender dysphoria, depression, anxiety, anger and distress over time without treatment. That specific conclusion was reiterated in the subsequent reviews cited. Your Friendly Neighborhood Sociologist ⚧ Ⓐ (talk) 21:28, 12 July 2024 (UTC)

I'm all for contextualisation, but could you perhaps point me to where this specific conclusion was reiterated in Taylor et al. (2024) or Ludvigsson et al. (2023)? Cixous (talk) 14:30, 13 July 2024 (UTC)